Skip to main content
Clinical Trials/NCT05226520
NCT05226520
Completed
Not Applicable

Effect of 6-week Probiotic Supplementation on Stress-related Parameters in Healthy Adults With Different Levels of Stress

Société des Produits Nestlé (SPN)1 site in 1 country49 target enrollmentDecember 16, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mild to Moderate Levels of Stress
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
49
Locations
1
Primary Endpoint
Salivary cortisol level
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a pilot exploratory study to investigate the effects of a probiotic Bifidobacterium longum NCC3001 intake on physiological and psychophysiological parameters related to stress in healthy individuals with mild to moderate stress level.

Detailed Description

The purpose of the study is to explore the effects of a probiotic Bifidobacterium longum NCC3001 intake on physiological and psychophysiological parameters related to stress in healthy individuals with mild to moderate stress level. The objectives is three: * Measure the effects of a 6-week supplementation with NCC3001 on psychological and physiological parameters in response to an acute experimental stress; * Measure the effects of a 6-week supplementation with NCC3001 on chronic stress level, gastro-intestinal symptoms and sleep quality; * Explore changes in the profiles of biological parameters associated with ingestion of NCC3001; including changes in hormones, neurotransmitters, circulating immune and microbiome-derived molecules and changes in the microbiome itself

Registry
clinicaltrials.gov
Start Date
December 16, 2020
End Date
May 31, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ability to understand and sign the informed consent
  • Healthy adult men and/or women aged 25 to 65 years old
  • Mild to moderate stress, defined as a score in the range of 15 to 25 on the validated Depression, Anxiety and Stress Scale (DASS-42)
  • Proficiency in French and/or English
  • Normal visual acuity and hearing with or without correction (self-reported)
  • BMI in the range of 18.5 to 29.9 kg/m2

Exclusion Criteria

  • Diagnosed food allergies
  • Currently participating or having recently participated in a clinical study with products potentially interfering with the results as judged by the investigator
  • Organic gastrointestinal pathology other than benign polyps, diverticulosis, hemorrhoids
  • Chronic or recurrent diarrhea with spontaneous bowel movements more often than 2 times daily
  • Concurrent diagnosed systemic chronic disease (e.g., endocrine, cardiovascular, metabolic, liver, celiac)
  • Willing to avoid the consumption of probiotic-containing products (including yogurts containing probiotics) i.e. any commercially available product specified as containing Lactobacillus, Bifidobacteria, Streptococcus or Saccharomyces for the 2 weeks prior to randomization visit
  • Willing to avoid the use of antibiotics in the 4 weeks prior to randomization visit
  • Adherence to an overly unbalanced diet such as vegan, paleo, ketogenic, low carbohydrate, raw diets
  • Conditions that may affect mood

Outcomes

Primary Outcomes

Salivary cortisol level

Time Frame: Before the stressor (time-point -20 minutes) and after the stressor (time-point +0 min, time-point +5 min, time-point +10 min, time-point +20 min, time-point +30 min, time-point +40 min) at both baseline and after 6 weeks of treatment

Salivary cortisol levels (nmol/L) before and after stressor

Secondary Outcomes

  • Probiotic in feces(Baseline and after 6 weeks treatment)
  • Mean heart rate variability(Baseline and after 6 weeks treatment)
  • Self-reported measures before and after the stressor (PANAS)(Baseline and after 6 weeks treatment)
  • Self-reported measures before, during and after the stressor (VAS)(Baseline and after 6 weeks treatment)
  • Self-reported endpoints from standard questionnaires (GSRS)(Baseline and after 6 weeks treatment)
  • Cortisol level from waking saliva samples(Baseline and after 6 weeks treatment)
  • Heart frequency(Baseline and after 6 weeks treatment)
  • Self-reported measures before and after the stressor (STAI-6)(Baseline and after 6 weeks treatment)
  • Mean skin conductance level(Baseline and after 6 weeks treatment)
  • Self-reported endpoints from standard questionnaires (HADs)(Baseline and after 6 weeks treatment)
  • Self-reported endpoints from standard questionnaires (Pittsburgh Sleep Quality)(Baseline and after 6 weeks treatment)
  • Self-reported endpoints from standard questionnaires (PSS)(Baseline and after 6 weeks treatment)
  • Microbiome related metabolites in stool, blood and urine(Baseline and after 6 weeks treatment)

Study Sites (1)

Loading locations...

Similar Trials